Skip to content

Acupuncture for Amnestic Mild Cognitive Impairment: a Pilot Multi-center, Randomized, Parallel Controlled Trial

Acupuncture for Amnestic Mild Cognitive Impairment: a Pilot Multi-center, Randomized, Parallel Controlled Trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021557
Enrollment
Unknown
Registered
2019-02-27
Start date
2019-07-01
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amnestic Mild Cognitive Impairment

Interventions

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of aMCI; 2. Informant Questionnaire on Cognitive Decline in the Elderly(IQCODE)scores>=51,<=53. 3. Aged 50-70 years, male or female; 4. Having sufficient visual and auditory resolution capability to accept neuropsychological testing; 5. Subjects volunteer and sign informed consent file.

Exclusion criteria

Exclusion criteria: 1. Educational attainment less than 6 years; 2. Hamilton Depression scale (HAMD) scores >=17 in patients with pseudodementia caused by depression or other emotional disorders; 3. Patients with congenital mental retardation, a family history of dementia, or a diagnosis of dementia, psychosis or other brain dysfunction caused by neuropsychological conditions; 4. Patients with a history of cerebrovascular diseases, including ischemic and hemorrhagic cerebrovascular disease. Patients with signs of neurological dysfunction such as hemiplegia, hemidysesthesia and aphasia in neurological examination; 5. Patients with secondary metabolic disorders caused by certain endocrine, genetic or neurological disorders. Patients with metabolic diseases induced by drugs; 6. Critical patients. Patients with histories of other central nervous system injuries, such as brain trauma, encephalitis, epilepsy, tumor, infection, severe liver and kidney dysfunction, blood disorders, central nervous demyelinative disease and degenerative diseases; 7. Patients with communication disorders that affect cognitive evaluation, such as speech, vision, hearing, and other serious disorders; 8. Patients with a history of alcohol or drug abuse, long term use of glucocorticoid, antipsychotics, sedatives, hypnotics, or other drugs that affect cognitive function; 9. Patients with snore symptoms (whether through systematic treatment or not), or have been diagnosed as sleep apnea syndrome after PSG examination; 10. Those who are participating in or have participated in other research projects in the last three months; 11. Those who have received acupuncture treatment in the past one month; 12. Those who are allergic to needles or alcohol; 13. Those who are positive in syphilis or HIV antibody examination; 14. Patients with vitamin B12 deficiency or thyroid dysfunction.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment (MoCA);

Secondary

MeasureTime frame
Alzheimer’s Disease Assessment Scale-Cognitive Section (ADAS-cog);Delayed Story Recall (DSR);Global Deterioration Scale (GDS);Latency and amplitude of Event-Related Potential P300;Magnetic Resonance Imaging(MRI);Functional magnetic resonance imaging(fMRI);Mini-mental State Examination (MMSE);Activity of Daily Life( ADL);Incidence of acupuncture adverse events;Clinical Dementia Rating (CDR);

Countries

China

Contacts

Public ContactZhang Liang

Clinical Medical College of Acupuncture, Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine

zhangliang307@foxmail.com+86 135 7093 7966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026